viernes, 20 de noviembre de 2026

Peptide market poised to explode with new Hims and Noom launches Despite lack of safety data, an HHS decision allows experimental compounds to go mainstream

https://www.statnews.com/2026/11/19/hims-noom-enter-peptide-market-mainstream-products-health-risks/?utm_campaign=daily_recap&utm_medium=email&_hsenc=p2ANqtz-_-DllYgyIZu72bsldAoOiYAk3aKFi0_Y4zM1BESWeryAelvejVTj9KWBsQVYh7LqwaRW0LtcUFj3mDjZGzUASonch8Yg&_hsmi=450317012&utm_content=450317012&utm_source=hs_email By Sarah Todd and Katie PalmerNov. 19, 2026 Peptides are poised to go mainstream with this week’s launches from telehealth companies Hims & Hers and Noom, both of which announced they will be offering prescriptions for eligible patients.

No hay comentarios: